Loading...
Market
Will RMC-6236 achieve its primary endpoint in the Phase 3 trial by December 31, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press release from Revolution Medicines or clinical trial results publication
Story
Revolution Medicines' RMC-6236 Shows Promising Data, Stock Rises 10-19%
Jul 15, 2024, 02:02 PM
Revolution Medicines (RVMD), a Redwood City-based clinical stage biotech, has announced promising interim clinical trial data for its investigational pancreatic cancer drug, RMC-6236. The drug, which is designed to inhibit all major forms of oncogenic RAS, showed a progression-free survival (PFS) of 8.1 months in second-line KRAS G12-mutant metastatic pancreatic cancer patients, significantly higher than the benchmark PFS of 2-3.5 months. The overall survival (OS) has not yet been reached, but it is already more than a year, compared to the benchmark OS of 6.1-6.9 months. The company plans to advance the 300 milligram dose of RMC-6236 into a Phase 3 study, comparing it to the investigator’s choice of standard chemotherapy among previously treated pancreatic cancer patients. The Phase 3 trial is expected to start before the end of the year. The announcement led to a pre-market increase of 10-19% in RVMD's stock price, although a reported rash adverse event (AE) might be problematic but seems manageable.
View original story
Similar markets
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Primary endpoint met with significant improvement • 25%
Primary endpoint met with moderate improvement • 25%
Primary endpoint not met • 25%
Trial inconclusive or delayed • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Highly Effective • 25%
Moderately Effective • 25%
Minimally Effective • 25%
Ineffective • 25%